Loading...
XASE
AIM
Market cap71mUSD
Dec 04, Last price  
1.47USD
1D
5.00%
1Q
-40.73%
Name

AIM ImmunoTech Inc

Chart & Performance

D1W1MN
XASE:AIM chart
P/E
—
P/S
418.59
EPS
—
Div Yield, %
—
Shrs. gr., 5y
72.73%
Rev. gr., 5y
3.96%
Revenues
170k
-15.84%
1,083,000933,0001,059,000265,000111,000135,000161,000213,000150,000197,000133,00092,000437,000367,000140,000163,000135,000141,000202,000170,000
Net income
-17m
L-40.20%
-13,213,000-19,399,000-18,139,000-12,219,000-13,438,000-13,136,000-9,015,000-17,354,000-16,225,000-17,450,000-15,230,000-7,502,000-8,259,000-9,813,000-10,826,000-16,258,000-21,513,000-21,086,000-28,962,000-17,320,000
CFO
-15m
L-29.99%
-7,236,000-13,747,000-15,112,000-9,358,000-9,297,000-11,886,000-10,096,000-13,136,000-16,830,000-13,918,000-16,053,000-7,380,000-7,941,000-10,640,000-9,067,000-10,368,000-13,965,000-16,108,000-21,267,000-14,888,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
URL
https://aimimmuno.com/
IPO date
Jul 12, 1996
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT